Oncotarget

Research Papers:

The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma

Kensuke Kojima _, Aya Maeda, Mariko Yoshimura, Yuki Nishida and Shinya Kimura

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:69625-69637. https://doi.org/10.18632/oncotarget.11904

Metrics: PDF 880 views  |   HTML 1289 views  |   ?  


Abstract

Kensuke Kojima1, Aya Maeda1, Mariko Yoshimura1, Yuki Nishida1, Shinya Kimura1

1Department of Hematology, Respiratory Medicine and Oncology, Division of Medicine, Saga University, Saga, Japan

Correspondence to:

Kensuke Kojima, email: kkojima@cc.saga-u.ac.jp

Keywords: PPM1D, p53, MDM2, p38 MAPK, mantle cell lymphoma

Received: March 22, 2016     Accepted: September 02, 2016     Published: September 08, 2016

ABSTRACT

PPM1D is a serine/threonine phosphatase that negatively regulates key DNA damage response proteins, such as p53, p38 MAPK, histone H2A.X, and ATM. We investigated the pathophysiological significance of PPM1D and its therapeutic targeting by the novel PPM1D inhibitor GSK2830371 in mantle cell lymphoma (MCL). Oncomine-based analyses indicated increased PPM1D mRNA levels in MCL cells compared with their normal counterpart cells. Higher PPM1D expression was associated with higher expression of the proliferation gene signature and poorer prognosis in patients. Eight MCL (three p53 wild-type and five mutant) cell lines were exposed to GSK2830371. GSK2830371 inhibited the cell growth, being prominent in p53 wild-type cells. GSK2830371 induced apoptosis in sensitive cells, as evidenced by induction of phosphatidylserine externalization and loss of mitochondrial membrane potential. p53 knockdown de-sensitized cell sensitivity. GSK2830371 increased the levels of total and Ser15-phosphorylated p53, and p53 targets p21 and PUMA. GSK2830371 and the MDM2 inhibitor Nutlin-3a acted synergistically in p53 wild-type cells. Interestingly, GSK2830371 sensitized MCL cells to bortezomib and doxorubicin in p53 wild-type and mutant cells; p38 signaling appeared to be involved in the GSK2830371/bortezomib lethality. PPM1D inhibition may represent a novel therapeutic strategy for MCL, which can be exploited in combination therapeutic strategies for MCL.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11904